Abstract
High–molecular weight (HMW) adiponectin may have the most biologic activity among
several isoforms. We investigated long-term effects of losartan on serum concentrations
of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS)
by serial measurements over 6 months. Forty hypertensive patients first received 50
mg of losartan. Upward titration of the losartan dose was implemented to reach a target
blood pressure of less than 140/90 mm Hg. Serum total adiponectin and HMW adiponectin
were measured at study entry (baseline), the 3-month treatment time point, and the
end of the 6-month period. Non-HMW adiponectin (ie, medium– and low–molecular weight
adiponectin) was calculated as total adiponectin − HMW adiponectin. Diagnosis of MS
was done by current standard criteria. In hypertensive patients without MS (n = 21),
the serum total adiponectin increased from 9.8 ± 5.4 μg/mL at baseline to 11.1 ± 6.2 μg/mL at 6 months (P < .01). Furthermore, the serum total adiponectin was significantly higher at 6 months
than at 3 months (P < .01). Serum HMW adiponectin also increased from 5.7 ± 3.9 μg/mL at baseline to 6.6 ± 4.4 μg/mL at 6 months (P < .01). In hypertensive patients with MS, the serum total adiponectin increased from
6.0 ± 2.7 μg/mL at baseline to 6.7 ± 3.3 μg/mL at 3 months and to 7.0 ± 3.1 μg/mL at 6 months (P < .01 for both). Furthermore, the serum HMW adiponectin concentration was significantly
higher at 6 months than at 3 months (P < .001). However, the serum non-HMW adiponectin concentration did not change during
treatment in either group. In conclusion, serum total and HMW adiponectin concentrations
increase after 6 months of losartan treatment in hypertensive patients, irrespective
of the presence or absence of MS.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The epidemiology of impaired glucose tolerance and hypertension.Am Heart J. 1991; 121: 1268-1273
- Prevalence of insulin resistance in essential hypertension.J Hypertens. 1995; 13: 1457-1462
- Do we need to target ‘prediabetic’ hypertensive patients?.J Hypertens. 2005; 23: 2119-2125
- Is there a rationale for angiotensin blockade in the management of obesity hypertension?.Hypertension. 2004; 44: 12-19
- Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.J Hypertens. 2002; 20: 1879-1886
- Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.J Hypertens. 2006; 2: 1405-1412
- Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.J Hypertens. 2006; 24: 11-25
- Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.J Clin Invest. 1997; 100: 2158-2169
- Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.Hypertension. 2003; 42: 76-81
- Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.Circulation. 2004; 110: 3687-3692
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.Nat Med. 2001; 7: 947-953
- The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.Nat Med. 2001; 7: 941-946
- Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun. 1999; 257: 79-83
- Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.Arterioscler Thromb Vasc Biol. 2000; 20: 1595-1599
- Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vasc Biol. 2003; 23: 85-89
- PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.Diabetes. 2001; 50: 2094-2099
- Plasma adiponectin complexes have distinct biochemical characteristics.Endocrinology. 2008; ([Epub ahead of print])
- Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.J Biol Chem. 2004; 279: 12152-12162
- A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin.J Lipid Res. 2006; 47: 1572-1582
- Comparison of serum high–molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.Diabetes. 2006; 55: 1954-1960
- Comparison of the effects of pioglitazone and voglibose on circulating total and high–molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with type 2 diabetes.Diabet Med. 2007; 24: 962-968
- Regulation of peroxisome proliferator–activated receptor gamma activity by losartan metabolites.Hypertension. 2006; 47: 586-589
- Thiazolidinediones.N Engl J Med. 2004; 351: 1106-1118
- Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001; 285: 2486-2497
- Review of the molecular pharmacology of losartan and its possible relevance to stroke prevention in patients with hypertension.Clin Ther. 2006; 28: 832-848
- Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.Circ Res. 2002; 90: 770-776
- Peroxisome proliferator–activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.J Biol Chem. 1997; 272: 3406-3410
- Adiponectin, cardiovascular function, and hypertension.Hypertension. 2008; 51: 8-14
- Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I.Eur J Endocrinol. 2006; 155: 293-296
- Banting lecture 1988. Role of insulin resistance in human disease.Diabetes. 1988; 37: 1595-1607
- Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.Circulation. 2004; 109: 433-438
- The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA. 2002; 288: 2709-2716
- Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.Circulation. 2003; 108: 414-419
- Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome.Diabetes Care. 2006; 29: 1357-1362
- Analysis of metabolic parameters as predictors of risk in the RENAAL study.Diabetes Care. 2003; 26: 1402-1407
- Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.Diabetes Care. 1979; 2: 120-126
- Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.Diabetes Care. 1993; 16: 434-444
- Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.Diabetes Care. 2001; 24: 1422-1427
- Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.Circulation. 2004; 110: 1572-1578
- Adverse prognostic significance of new diabetes in treated hypertensive subjects.Hypertension. 2004; 43: 963-969
- Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.Diabetes Care. 2003; 26: 1745-1751
- Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study.Diabetes Care. 2003; 26: 2015-2020
Article info
Publication history
Accepted:
April 22,
2008
Received:
December 27,
2007
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
